The Big Heart Disease Lie

Holistic Treatments to Reverse Heart Disease

Get Instant Access

1. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;12:951-957.

2. Stein EA. Identification and treatment of individuals at high risk of coronary artery disease. Am J Med 2002;112(8A).

3. Wilson PWF, D'Agostino RB, Levy D, Belanger, AJ, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.

4. D'Agostino RB, Russel MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-281.

5. McMurray JC, Pfeffer MA. New therapeutic options in congestive heart failure. Circulation 2002;105:2099-2106.

6. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998;80:35-47.

7. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000;6:433-440.

8. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80(11A):15L-25L.

9. Givertz MM, Colucci WS. New targets for heart failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998;352(Suppl 1):S134-S138.

10. Svensson EC, Marshall DJ, Woodard K, et al. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 1999;99:201-205.

11. Kaplitt MG, Xiao X, Samulski RJ, et al. Long term gene transfer in porcine myocardium after coronary infusion of and adeno-associated virus vector. Ann Thorac Surg 2000;62:1669-1676.

12. Kimura B, Mohuczy D, Tang X, Phillips MI. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensin antisense. Hypertension 2001;37:376-380.

13. Asahara T, Murohara T, Sullivan A, et al. Isolation of putatitve progenitor endothelial cells for angio-genesis. Science 1997;275:964-967.

14. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nature Med 2001;4:430-436.

15. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999;103:697-705.

16. Jackson K, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001;107:1395-1402.

17. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000;7:31-34.

18. Akhtar S, Hughes MD, Khan A, et al. The delivery of antisense therapeutics. Adv Drug Del Rev 2000;44:3-21.

19. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy strategy" strategy as a means of gene thereapy and study of gene expression in cardiovascular disease. Circ Res 1998;82:1023-1028.

20. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.

21. Matsui T, Li L, Del Monte F, et al. Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 1999;100:2373-2379.

22. Melo LG, Agrawal R, Zhang L, et al. Gene Therapy strategy for long term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002;105:602-607.

23. Brauner R, Nonoyama M, Laks H, et al. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J Thorac Cardiovasc Surg 1997;114:923-933.

24. Simons M, Edeelman ER, DeKeyser JL, Langer R, Rosenberg RD Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle accumulation in vivo. Nature 1992;359:67-70.

25. Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically-engineered rabbit vein grafts. J Clin Invest 1997;99:1295-1301.

26. Hannon GJ. RNA interference. Nature 2002;418:244-251.

27. Morishita R, Gibbons GH, Ellison KE, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-5859.

28. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor factor kB binding sites prevents myocardial infarction. Nat Med 1997;3:894-899.

29. Isner JM. Myocardial gene therapy. Nature 2002;415:234-239.

30. Alexander MY, Webster KA, McDonald PH, Prentice HW. Gene transfer and models of gene therapy for the myocardium. Clin Exp Pharnacol Physiol 1999;26:661-668.

31. Wright MJ, Wightman LML, Lilley C, et al. In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors. Bas Res Cardiol 2001;96:227-236.

32. Losordo DW, Vale PR, Isner JM. Gene therapy for myocardial angiogenesis. Am Heart J 1999;138:S132-S141.

33. Prentice H, Bishopric N, Hicks MN, et al. Regulated expression of a foreign gene targeted to the ischemic myocardium. Cardiovasc Res 1997;35:567-574.

34. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumour-specific gene therapy. Gene Ther 2000;7:493-498.

35. Nicklin SA, Buening H, Dishart KL, et al. Efficient and selective AAV-2 mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001;4:174-181.

36. Lee LY, Patel SR, Hackett NR, et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000;69:14-24.

37. Song YK, Liu F, Chu S, Liu D. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Human Gene Ther 1997;8:1585-1594.

38. Labhasetwar V, Bonadio J, Goldstein S, Chen W, Levy RJ. A DNA controlled-release coating for gene transfer: transfection in skeletal and cardiac muscle. J Pharm Sci 1998;87:1347-1350.

39. Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear localization signals for non viral gene transfer systems. Gene Ther 2002;9:157-167.

40. Harrison RL, Byrne BJ, Tung L. Electroporation-mediated gene transfer in cardiac tissue. FEBS Lett 1998;435:1-5.

41. Mann DL. Mechanisms and models in heart failure. A combinatorial approach. Circulation 1999;100:999-108.

42. Shyu KG, Wang MT, Wang BW, et al. Intrmyocardial injection of naked DNA encoding HIF-1 a/VP16 hybrid to enhnance angiogenesis in an acute myocardial infarction model in the rat. Caridovasc Res 2002;54:576-583.

43. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996;93:11,421-11,425.

44. Poston RS, Tran KP, Mann MJ, Hoyt EG, Dzau VJ, Robbins RC. Prevention of ischemically-induced neointimal hyperplasia using ex vivo antisense oligodeoxynucleotides. J Heart Lung Transplant 1998;17:349-355.

45. Krasnykh VN, Douglas JT, van Beusechem VW. Gene targeting of adenoviral vectors. Mol Ther 2000;1:391-405.

46. Mah C, Byrne BJ, Flotte TR. Virus-based gene delivery systems. Clin Pharmacokinet 2002;41:901-911.

47. Hartigan-O'Connor D, Amalfitano A, Chamberlain JS. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 1999;73:7835-7841.

48. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson JM. Immune response to adenovirus and adenoassociated virus in humans. Gene Ther 1999;6:1574-1583.

49. Yan Z, Zhang Y, Duan D, Engelheardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000;97:6716-6721.

50. Hu W-S, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev 2000;52:493-511.

51. Daly G, Chernajovski Y. Recent developments in retroviralk-mediated gene transduction. Mol Ther 2000;2:423-434.

52. Sakoda T, Kasahara N, Hamamori Y, Kedes L. A high titer lentiviral production system mediates transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol 1999;31:2037-2047.

53. Zhao J, Pettigrew GJ, Thomas J, et al. Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo. Basic Res Cardiol 2002;97:348-358.

54. Coffin RS, Howard MK, Cummings DV, et al. Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Ther 1996;3:560-566.

55. Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin Biol Ther 2001;1:177-191.

56. Datwyler DA, Eppenberger HM, Koller D, Bailey JE, Magyar JP. Efficient gene delivery into adult cardiomyocytes by recombinant Sindis virus. J Mol Med 1999;77:859-864.

57. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002;105:732-738.

58. Griffiths I, Binley K, Iqball S, et al. The macrophage—a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000;7:255-262.

59. Magnani M, Rossi L, Fraternale A, et al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther 2002;9:749-751.

60. Funk M, Krumholz HM. Epidemiologic and economic impact of advanced heart failure. J Cardiovasc Nurs 1996;10:1-10.

61. Carden DL, Granger DN. Pathophysiology of ischemia-reperfusion injury. Am J Pathol 2000;190:255-266.

62. Yellon DM, Baxter GF. Reperfusion injury revisited. Is there a role for growth factor signalling in limiting lethal reperfusion injury? Trends Cardiovasc Med 2000;9:245-249.

63. Braunwald E, Kloner RA. Myocardial reperfusion: a double edged sword. J Clin Invest 1985;76:1713-1719.

64. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodelling in rat myocardial infarction. Am J Physiol 1991;260:H1406-H1414.

65. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of metlloprotease and tissue inhibitor expression during heart failure progression in the infarcted heart. Cardiovasc Res 2000;46:307-315.

66. Mehta JL, Li DY. Inflammation in ischemic heart disease: Response to tissue injury or a pathogenic villain? Cardiovasc Res 1999;43:291-299.

67. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 1998;40:436-442.

68. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.

69. Ware JH, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997;3:158-164.

70. Tio RA, Tkebuchava T, Scheurermann TH, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral blood flow to ischemic myocardium. Human Gene Ther 1999;10:2953-2960.

71. Mack CA, Patel SA, Schwarz EA, et al. Biological bypass with the use of adenovirus-mediated transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998;115:168-177.

72. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-539.

73. Ueno H, Li JJ, Masuda S, Qi Z, Yamamoto H, Takeshita A. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 1997;17:2453-2460.

74. Ueda H, Sawa Y, Matsumoto K, et al. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thorac Surg 1999;67:1726-1731.

75. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-837.

76. Hammond HK, McKirman MD. Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials. Cardiovasc Res 2001;49:561-567

77. Tabata H, Silver M, Isner JM. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc Res 1997;25:470-479.

78. Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002;40:47-53.

79. Aoki M, Morishita R, Taniyama Y, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by hepatocyte growth factor: potential gene therapy for ischemic diseases. J Atheroscler Thromb 2000;7:71-76.

80. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001;103:2138-2143.

81. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297.

82. Bashir R, Vale PR, Isner JM, Losordo DW. Angiogenic gene therapy: pre-clinical studies and phase I clinical data. Kideny Int 2002;61(Suppl 1):110-114.

83. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-1912.

84. Williams RS, Benjamin IJ. Protective responses of the ischemic myocardium. J Clin Invest 2000;106:813-818.

85. Li Q, Bolli R, Qiu Y, Tang X-L, Guo Y, French BA. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation 2001;103:1893-1898.

86. Chen EP, Bittner HB, Davis RD, Van Trigt P, Folz RJ. Physiological effects of extracellular superoxide dismutase transgene overexpression on myocardial function after ischemia and reperfusion injury. J Thorac Cardiovasc Surg 1998;115:450-458.

87. Agrawal RS, Muangman S, Melo LG, et al. Recombinant adeno-associated virus mediated antioxidant enzyme delivery as preventive gene therapy against ischemia-reperfusion injury of the rat myocardium. Mol Ther 2001;3:A837.

88. Li Q, Bolli R, Qiu Y, Tang XL, Murphree SS, French BA. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation 1998;98:1438-1448.

89. Zhu HL, Stewart AS, Taylor MD. Blocking free radical production via adenoviral gene transfer decreases cardiac ischemia-reperfusion injury. Mol Ther 2000;2:470-475.

90. Yoshida T, Watanabe M, Engelman DT, et al. Transgenic mice overespressing glutathione peroxidase are resistant to myocardial reperfusion injury. J Mol Cell Cardiol 1996;28:1759-1767.

91. Suzuki K, Sawa Y, Kaneda Y. In vivo gene transfer of heat shock protein 70 enhances myocardial tolerance to ischemia-reperfusion injury in rat. J Clin Invest 1997;99:1645-1650.

92. Vander Heide RS. Increased expression of HSP27 protects canine myocytes from simulated ischemia-reperfusion injury. Am J Physiol 2002;282:H935-H941.

93. Chatterjee S, Stewart AS, Bish LT, et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic ischemic heart failure. Circulation 2002;106(Suppl):I212-I217.

94. Yang Z, Cerniway RJ, Byford AM. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol 2002;282:H949-H955.

95. Agata J, Chao L, Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002;40:653-659.

96. Holly TA, Drincic A, Byun Y, Nakamura S, Kloche FJ, Cryns VL. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 1999;31:1709-1715.

97. Chen H, Mohuczy D, Li D, et al. Protection against ischemia/reperfusion injury and myocardial dysfunction by antisense-oligodeoxyynucleotide directed at angiotensin-converting enzyme mRNA. Gene Ther 2001;8:804-810.

98. Stepkowski SM. Development of antisense oligodeoxynucleotides for transplantation. Curr Opin Mol Ther 2000;2:304-317.

99. Poston RS, Mann MJ, Hoyt EG, Ennen M, Dzau VJ, Robbins RC. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, non-toxic, highly efficient transfection method. Transplantation 1999;68:825-832.

100. St. John Sutton MG, Sharpe N. left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation 2000;101:2981-2988.

101. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.

102. Asakura M, Kitakaze M, Taskashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nature Med 2002;8:35-40.

103. Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 2002;20:969-975.

104. Taigen T, Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000;97:1196-1201.

105. Li Q, Li B, Wang X, et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997;100:1991-1999.

106. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase kinase 3-ß suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002;99:907-912.

107. Nozato T, Ito H, Watanabe M, et al. Overexpression of Cdk inhibitor p16 by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy. J Mol Cell Cardiol 2001;33:1493-1504.

108. Tamamori M, Ito H, Hiroe M, Terada Y, Marumo F, Ikeda M. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Am J Physiol 1998;275:H2036-H2040.

109. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase delivery. Hypertension 1997;30:307-3113.

110. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in salt-sensitive rats. Hum Gene Ther 1998;9:1429-1438.

111. Yoshida H, Zhang JJ, Chao L, Chao J. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 2000;35:25-31.

112. Shi Q, Raffi S, Wu MH, et al. Evidence for circulating bone marrow derived endothelial cells. Blood 1998;92:362-367.

113. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization Circ Res. 1999;85:221-228.

114. Shintani S, Murohara T, Ikeda H, et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 2001;103:897-903.

115. Kawamoto A, Gwon H-C, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001;103:634-637.

116. Ikenaga S, Hamano K, Nishida M, et al. Autologous bone marrow implantation induced angiogenesis and improved deteriorated exdercise capacity in a rat ischemic hindlimb model. J Surg Res 2001;96:277-283.

117. Murohara T, Ikeda H, Duan J, et al. Transplanted chord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000;105:1527-1536.

118. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells foe therapeutic neovascularization. Proc Natl Acad Sci USA 2000;97:3422-3427.

119. Fuchs S, Baffour R, Zhou YF, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001;37:1726-1732.

120. Vasa M, Fichtscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7.

121. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.

122. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incroporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-3024.

123. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. New Engl J Med 2001;344:175-1757.

124. Soonpaa MH, Field L. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res 1998;83:15-26.

125. Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 1996;28:1737-1746.

126. Reinlib L, Field L. Cell transplantation as future therapy for cardiovascular disease? Circulation 2000;101:e192-e197.

127. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improves performance after skeletal myoblast transplantation. Nat Med 1998;4:929-933.

128. Min JY, Yang Y, Converso KL, et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol 2002;92:288-296.

129. Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999;100(Suppl):II247-II256.

130. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-49.

131. Hakuno D, Fukuda K, Makino S, et al. Bone marrow-derived regenerated cardiomyocytes (CMG cells) express functional adrenergic and muscarinic receptors. Circulation 2002;105:380-386.

132. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:710-705.

133. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl Acad Sci USA 2001;98:10,344-10,349.

134. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med 2002;346:5-15.

135. Muller P, Pfeiffer P, Koglin J, et al. Cardiomyocytes of non cardiac origin in myocardial biopsies of human transplanted hearts Circulation 2002;106:31-35.

136. Taylor DA, Hruban R, Rodriguez R, Goldschmidt-Clermont PJ. Cardiac chimerism as a mechanism for self-repair. Does it happen and if so to what degree. Circulation 2002;106:2-4.

137. Laflamme MA, Myerson D, Saffitz JE, Murry CE. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res 2002;90:634-640.

138. Strauer BE, Brehm M, Zeus T, et al. Myocardial regeneration after intracoronary transplantation of human autologous stem cells following acute myocardial infarction. Dtsch Med Wochenschr 2001;126:932-938.

Was this article helpful?

0 0
Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook

Post a comment